Erlotinib

What is Erlotinib?

Erlotinib is a medication primarily used in oncology, classified as a targeted therapy. It is designed to treat specific types of cancer by focusing on particular molecules involved in cancer cell growth and survival, rather than indiscriminately attacking all rapidly dividing cells like traditional chemotherapy. Marketed under the brand name Tarceva, Erlotinib belongs to a class of drugs known as kinase inhibitors. More specifically, it is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, meaning it blocks signals that cancer cells need to grow and divide, especially in cancers where the EGFR pathway is overactive or mutated.

How Does it Work?

The mechanism of action for Erlotinib centers on its ability to inhibit the epidermal growth factor receptor (EGFR). EGFR is a protein on cell surfaces that regulates growth, division, and survival. In many cancers, particularly non-small cell lung cancer (NSCLC), the EGFR gene can be mutated or overexpressed, leading to uncontrolled cell proliferation. Erlotinib works by reversibly binding to the ATP binding site of the EGFR tyrosine kinase enzyme. This action prevents the phosphorylation of the receptor, thereby blocking downstream signaling pathways crucial for cell proliferation, angiogenesis (new blood vessel formation), and metastasis. By disrupting these growth signals, Erlotinib effectively slows or halts cancer progression, offering a precise approach for patients with specific genetic tumor characteristics.

Medical Uses

Erlotinib is primarily indicated for the treatment of certain advanced or metastatic cancers. Its most significant use is in non-small cell lung cancer (NSCLC). It is approved for patients with NSCLC whose tumors harbor specific activating mutations of the EGFR gene, as identified by an FDA-approved test. In this setting, it can serve as a first-line treatment or for patients whose disease has progressed after previous chemotherapy. For those without these specific mutations, its efficacy is considerably lower.

Another important indication for Erlotinib is in pancreatic cancer. It is used in combination with gemcitabine as a first-line treatment for patients with locally advanced, unresectable, or metastatic pancreatic cancer. This combination therapy has demonstrated improved overall survival in this challenging disease, highlighting the importance of biomarker testing for appropriate patient selection for this targeted cancer therapy.

Dosage

The dosage of Erlotinib varies based on the specific cancer being treated and individual patient factors. It is administered orally, typically as a single tablet once daily. For optimal absorption, Erlotinib should be taken at least one hour before or two hours after a meal.

• For non-small cell lung cancer, the usual daily dose is 150 mg.
• For pancreatic cancer, when used with gemcitabine, the recommended daily dose is typically 100 mg.

Dosage adjustments may be necessary due to side effects or liver impairment. Patients must strictly follow their prescribed dosage and schedule and should never adjust the dose without consulting their healthcare provider. Regular monitoring and communication with the oncology team are crucial throughout treatment.

Side Effects

Like all medications, Erlotinib can cause side effects, ranging from mild to severe. Common side effects often include:

• Skin rash (acne-like)
• Diarrhea (potentially severe, leading to dehydration)
• Fatigue
• Nausea and vomiting
• Loss of appetite
• Dry skin
• Hair thinning
• Eye irritation (conjunctivitis)

More serious, though less common, side effects require immediate medical attention:

• Interstitial Lung Disease (ILD): Symptoms like new or worsening shortness of breath, cough, or fever.
• Gastrointestinal perforation: Severe abdominal pain, fever, nausea, vomiting.
• Liver problems: Yellowing of skin or eyes, dark urine, severe nausea, vomiting.
• Severe skin reactions: Blistering, peeling, or widespread rash.

Patients should promptly discuss any experienced side effects with their doctor, who can provide guidance on management or treatment adjustments.

Drug Interactions

Erlotinib is primarily metabolized by the cytochrome P450 (CYP) enzyme system, particularly CYP3A4. This means it can interact with other drugs affecting this system, potentially altering Erlotinib's effectiveness or increasing the risk of side effects.

• CYP3A4 Inhibitors: Drugs like ketoconazole, erythromycin, or grapefruit juice can increase Erlotinib levels, potentially leading to more severe side effects.
• CYP3A4 Inducers: Drugs such as rifampin, phenytoin, carbamazepine, or St. John's Wort can decrease Erlotinib levels, reducing its efficacy.
• Gastric pH-altering agents: Medications that reduce stomach acid (e.g., proton pump inhibitors, H2-receptor antagonists) can decrease Erlotinib's solubility and absorption, leading to lower drug concentrations. Concomitant use should generally be avoided or managed with careful timing.
• Warfarin: Co-administration with warfarin may increase the risk of bleeding, requiring close monitoring of INR.

Patients should always inform their healthcare provider about all medications, supplements, and herbal products they are taking to prevent potential drug interactions.

FAQ

Is Erlotinib a chemotherapy drug?

No, Erlotinib is not considered traditional chemotherapy. It is a targeted therapy that specifically blocks signals for cancer cell growth, unlike chemotherapy which generally targets all rapidly dividing cells.

Can I take Erlotinib with food?

No, Erlotinib should be taken on an empty stomach. It is recommended to take it at least one hour before or two hours after a meal to ensure proper absorption and effectiveness.

What are alternatives to Erlotinib?

Yes, for EGFR-mutated NSCLC, other EGFR inhibitor drugs exist, such as gefitinib, afatinib, osimertinib, and dacomitinib. The choice of therapy depends on the specific mutation, prior treatments, and patient characteristics.

Products containing Erlotinib are available through trusted online pharmacies. You can browse Erlotinib-based medications at ShipperVIP or Medicenter.

Summary

Erlotinib remains a vital targeted therapy for certain cancers, notably non-small cell lung cancer with activating EGFR mutations and pancreatic cancer. By specifically inhibiting the epidermal growth factor receptor, it disrupts critical pathways essential for cancer cell proliferation and survival. While effective for appropriately selected patients, it is associated with various side effects, and its efficacy can be influenced by interactions with other medications. The judicious use of Erlotinib, guided by genetic testing and close medical supervision, underscores its role as a cornerstone in personalized cancer treatment, offering improved outcomes for many patients.